C. Assaf

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
C. Assaf, Ch Assaf, Chalid Assaf, C Assaf, Ch. Assaf
Publication record
161 papers · 5,913 citations · H-index 39

PAPERS

Corrigendum to 'Resistance of Cutaneous Anaplastic Large-Cell Lymphoma Cells to Apoptosis by Death Ligands Is Enhanced by CD30-Mediated Overexpression of c-FLIP': Journal of Investigative Dermatology, Volume 130, Issue 3, March 2010, Pages 826-840.
20250 citationsauthor #5
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
2023120 citationsauthor #2
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
202328 citationsauthor #4
Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial
20232 citationsauthor #1
ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides
20230 citationsauthor #20
The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)
202210 citationsauthor #1
Care structure of patients with mycosis fungoides and Sézary syndrome in Germany – Care research based on SHI claims data
20227 citationsauthor #1
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data
20227 citationsauthor #3
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
202211 citationsauthor #3
Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced CTCL
20223 citationsauthor #2
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021
202244 citationsauthor #2
Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers
202210 citationsauthor #8
Bendamustine monochemotherapy in aggressive or advanced‐stage primary cutaneous T‐cell lymphomas
20221 citationsauthor #4
Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma
20220 citationsauthor #5
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
202227 citationsauthor #2
Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
202212 citationsauthor #6
Dimethyl fumarate (DMF) therapy in CTCL: final results from a clinical phase II study
20220 citationsauthor #3
CD74 overexpression in cutaneous T-cell lymphoma and its inhibition as a potential therapeutic approach
20210 citationsauthor #5
Human Papillomavirus‐type distribution in anogenital lesions of prepubertal children
20212 citationsauthor #9
Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
202112 citationsauthor #1
Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study.
20219 citationsauthor #3
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.
202118 citationsauthor #6
Paraneoplastic Filiform Hyperkeratosis and Immunoglobulin-Associated Vasculitis in Myeloma Progression: A Case Report
20215 citationsauthor #4
Incidence and mortality of cutaneous lymphoma in North-Rhine Westphalia/Germany: recent trends and data of the population-based cancer registry of North Rhine Westphalia
20210 citationsauthor #5
Cancer-Associated Fibroblasts Play an Important Role in Early-Stage Mycosis Fungoides.
20216 citationsauthor #1
Response to brentuximab vedotin in advanced stage MF/Sézary syndrome with low CD-30 expression: “real-life” data of the German Cutaneous Lymphoma Network
20211 citationsauthor #17
Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides
202117 citationsauthor #3
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network
202111 citationsauthor #13
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
20212 citationsauthor #5
Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma
202136 citationsauthor #35
Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network
20219 citationsauthor #12
Quality of life in mycosis fungoides and Sézary-syndrome patients undergoing low-dose total skin electron beam therapy with or without maintenance therapy.
202112 citationsauthor #11
Bendamustine Monotherapy for Primary Cutaneous Gamma-Delta T-Cell Lymphoma.
20205 citationsauthor #5
[Anakinra therapy in a patient with multifocal pyoderma gangrenosum and hidradenitis suppurativa].
20203 citationsauthor #3
European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1
202073 citationsauthor #4
Cutaneous Vasculitis in a Patient With COVID-19
20206 citationsauthor #7
Evaluation of blood Sézary markers by means of correlation with apoptosis resistance and clonality
20190 citationsauthor #2
Low-dose gemcitabine therapy in CTCL: ‘real-life” data of the German Cutaneous Lymphoma Network
20191 citationsauthor #11
Primary cutaneous diffuse large B‐cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences
201923 citationsauthor #5
Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
20191 citationsauthor #6
SURVIVAL AMONG A PATIENT COHORT OF RELAPSED/REFRACTORY MYCOSIS FUNGOIDES IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM
20192 citationsauthor #13
Quality of Life Improvement Following Low-Dose Total Skin Electron Beam Therapy in Patients with Mycosis Fungoides or Sezary Syndrome
20190 citationsauthor #5
Key Role of Reactive Oxygen Species (ROS) in Indirubin Derivative-Induced Cell Death in Cutaneous T-Cell Lymphoma Cells
201918 citationsauthor #3
Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom
20190 citationsauthor #14
PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM
20190 citationsauthor #13
CD30 expression in rare cutaneous lymphomas
20190 citationsauthor #11
Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome
201920 citationsauthor #5
Identification of mineralocorticoid and glucocorticoid receptors on peripheral nociceptors: Translation of experimental findings from animal to human biology.
201910 citationsauthor #4
Defining B2 involvement in Sezary syndrome results from the PROCLIPI study
20190 citationsauthor #20
Tumors in Pigmented Skin
20181 citationsauthor #1
Genome-Wide Analysis of Interchromosomal Interaction Probabilities Reveals Chained Translocations and Overrepresentation of Translocation Breakpoints in Genes in a Cutaneous T-Cell Lymphoma Cell Line
20187 citationsauthor #4
Pigmented Ethnic Skin and Imported Dermatoses
201810 citationsauthor #3
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow‐up (ICD10 C82 ‐ C86)
201843 citationsauthor #2
Asymptomatic erythematous‐violaceous scrotal vesicles in a 78‐year‐old man
20170 citationsauthor #3
King’s Research Portal
20170 citationsauthor #3
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
2017430 citationsauthor #3
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
2017510 citationsauthor #51
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 ‐ C86)
201722 citationsauthor #2
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines
20162 citationsauthor #6
Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study.
201621 citationsauthor #5
Inactivation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma.
201615 citationsauthor #10
Mac attack: macrophages as key drivers of cutaneous T‐cell lymphoma pathogenesis
201621 citationsauthor #1
Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
201689 citationsauthor #7
Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.
201526 citationsauthor #14
Electrochemotherapy in advanced skin tumors and cutaneous metastases – a retrospective multicenter analysis
201548 citationsauthor #6
A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.
20151 citationsauthor #9
Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop
201599 citationsauthor #2
Neutrophil rich CD30 Positive Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature
20150 citationsauthor #3
Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases
201578 citationsauthor #9
T‐cell receptor gene rearrangement analysis of sequential biopsies in cutaneous T‐cell lymphomas with the Biomed‐2 PCR reveals transient T‐cell clones in addition to the tumor clone
201412 citationsauthor #6
83 cases and prognostic factors. An EORTC Cutaneous Lymphoma Group study of Subcutaneous panniculitis-like T-cell lymphoma: definition, classification
20130 citationsauthor #20
Guidelines on the use of extracorporeal photopheresis
2013218 citationsauthor #14
Brief S2k guidelines – Merkel cell carcinoma
201320 citationsauthor #2
demonstrates a common clonal T-cell origin Single-cell analysis of CD30+ cells in lymphomatoid papulosis
20130 citationsauthor #1
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
2013131 citationsauthor #8
Intralymphatic Histiocytosis following Orthopaedic Metal Implant Intralymphatische Histiozytose nach orthopädischer Metallimplantation
20130 citationsauthor #3
Response Of Rare Variants Of Cutaneous T Cell Lymphoma (CTCL) To Treatment With Bexarotene. A Prospective German DeCOG Trial
20137 citationsauthor #24
Treatment of advanced cutaneous T‐cell lymphomas with non‐pegylated liposomal doxorubicin – Consensus of the lymphoma group of the Working Group Dermatologic Oncology
20139 citationsauthor #1
Brief S2k guidelines – Cutaneous lymphomas
201340 citationsauthor #2
Molecular diagnostics in cutaneous lymphomas
201319 citationsauthor #6
Histopathology of Sèzary syndrome in contrast to other erythrodermic skin diseases.
20130 citationsauthor #8
Intralymphatic Histiocytosis following Orthopaedic Metal Implant
20133 citationsauthor #3
Diagnostics of autoimmune bullous diseases in German dermatology departments
201223 citationsauthor #4
Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
201213 citationsauthor #5
The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome
201232 citationsauthor #7
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
201264 citationsauthor #17
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
201146 citationsauthor #18
cFLIP diminishes CD95-induced apoptosis of CD30-stimulated cutaneous anaplastic large T cell lymphoma (cALCL) cells: Apoptoseresistenz durch CD30-induzierte cFLIP-Expression
20100 citationsauthor #4
Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.
201020 citationsauthor #4
Treatment of Cutaneous Lymphomas
20100 citationsauthor #1
Evaluation of T-cell Clonality in Archival Skin Biopsy Samples of Cutaneous T-cell Lymphomas Using the Biomed-2 PCR Protocol
201033 citationsauthor #4
Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.
201025 citationsauthor #5
Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas.
201034 citationsauthor #4
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
2010211 citationsauthor #5
Diagnostic tools in Sezary syndrome.
20107 citationsauthor #6
Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response
20100 citationsauthor #5
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma
2009104 citationsauthor #6
Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders.
200923 citationsauthor #7
Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis‐like T‐cell non‐Hodgkin lymphoma
20099 citationsauthor #18
Hepatosplenic T‐cell lymphomas and therapy with TNF‐α‐blocking biologics: a risk for psoriasis patients?
200911 citationsauthor #4

TIMELINE

1996 228 citations

1999 155 citations

2000 337 citations

2002 168 citations

2003 118 citations

2004 98 citations

2005 72 citations

2006 476 citations

2007 427 citations

2008 430 citations

2009 369 citations

2010 330 citations

2011 46 citations

2012 132 citations

2013 447 citations

2014 12 citations

2015 252 citations

2016 148 citations

2017 962 citations

2018 61 citations

2019 75 citations

2020 87 citations

2021 140 citations

2022 132 citations

2023 150 citations

2025 0 citations

Unknown 67 citations

C. Assaf

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT